Today: 30 June 2026
Oracle stock price slips again as bondholder lawsuit keeps AI debt fears in play

Oracle stock price slips again as bondholder lawsuit keeps AI debt fears in play

New York, Jan 16, 2026, 10:42 EST — Regular session

  • Oracle shares dipped roughly 1% in early trading, deepening a midweek drop triggered by a bondholder lawsuit.
  • The complaint focuses on disclosures related to debt incurred for a massive AI infrastructure project linked to OpenAI.
  • Credit markets remain uneasy over the potential volume of new borrowing required by “hyperscalers” this year.

Oracle shares slipped roughly 1% to $188 Friday morning, as investors grappled with fallout from bondholders suing the company over alleged disclosure lapses connected to its sizable debt issuance for AI expansion.

The case arrives amid a market already bracing for a surge in borrowing from the biggest AI infrastructure spenders. Barclays is forecasting a rise in U.S. corporate bond issuance in 2026. Meanwhile, a BofA Securities report highlighted Amazon, Alphabet’s Google, Meta, Microsoft, and Oracle as the “Big Five” group that saw a sharp increase in bond sales last year. Reuters

It’s significant now since equity traders are pricing Oracle’s stock as a gauge of funding costs. When credit spreads widen, the fallout is straightforward: more expensive debt, tighter capital budgets, and reduced slack for unexpected setbacks.

On Thursday, Oracle executive Doug Kehring submitted a Form 144, revealing plans to sell 35,000 Oracle shares valued at roughly $6.82 million.

Form 144 serves as a heads-up from insiders aiming to sell restricted or control securities. It doesn’t confirm a sale has taken place, but it often draws investor focus when a stock faces selling pressure.

That said, the real weight behind Oracle’s next move probably lies in its debt situation, not minor insider trades. Investors want to gauge how fast AI infrastructure spending turns into steady cash flow — and how frequently Oracle will need to return to the capital markets in the process.

The stock’s move might be jumping the gun. Lawsuits could get tossed out or scaled back, and these legal processes take time. For bulls, the main worry is clear: a fresh surge in borrowing that drives up funding costs and weighs on sentiment.

U.S. markets shut Monday for Martin Luther King Jr. Day, giving traders a three-day stretch without the usual chances to adjust positions.

Next on deck: Tuesday’s reopen, plus any new court filings or credit-market cues that reveal if the strain is easing or spreading.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Celestica Inc. (CLS) Draws Market Interest on AI, Energy Momentum
    June 30, 2026, 5:53 AM EDT. Celestica Inc. (CLS) has beaten Nvidia's gains over the past three years as demand from artificial intelligence (AI) and energy transition pushes growth. Shares sit about 20% below all-time highs and the Zacks price target as the stock faces some pressure. The company is guiding for double-digit sales and earnings growth in 2025 and 2026, pointing to strong revenues on the back of demand from data centers, semiconductors and energy storage markets. Celestica's operations split into Advanced Technology Solutions and Connectivity & Cloud Solutions, covering design, manufacturing and logistics. CEO Rob Mionis said demand remains solid and flagged new AI program wins, mentioning a 1.6 terabyte switching project with a hyperscaler. CLS trades at a discount to the Zacks Tech Sector, which bulls call attractive for buy-and-hold tech investors.
Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Previous Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Merck stock slips as FDA fast-track questions build and earnings near
Next Story

Merck stock slips as FDA fast-track questions build and earnings near

Go toTop